Combatting Police Discrimination in the Age of Big Data
In: 20 New Crim. L. Rev. 181 (2017)
378883 Ergebnisse
Sortierung:
In: 20 New Crim. L. Rev. 181 (2017)
SSRN
In: Teze de doctorat 20
In: Seria Argonaut
In: Theologia
In: 20 Lewis & Clark Law Review 717 (2016)
SSRN
In: Young Arbitration Review, Edn. 20, January 2016
SSRN
In: The Social Sciences 11 (1): 20-28
SSRN
In: J Internet Bank Commer 2015, 20:3
SSRN
In: 20 Lewis & Clark L. Rev. 165 (2016)
SSRN
In: 31(4) SUFFOLK LAW. 20 (Dec. 2015)
SSRN
In: Familie - Unternehmen - Öffentlichkeit : Thyssen im 20. Jahrhundert 3
In: http://www.amb-express.com/content/5/1/20
Abstract In Brazil, there is a growing demand for specialised pharmaceuticals, and the high cost of their importation results in increasing costs, reaching US$ 1.34 billion in 2012 and US$ 1.61 billion in 2013. Worldwide expenses related to drugs could reach US$ 1.3 trillion in 2018, especially due to new treatments for hepatitis C and cancer. Specialised or high-cost pharmaceutical drugs used for the treatment of viral hepatitis, multiple sclerosis, HIV and diabetes are distributed free of charge by the Brazilian government. The glucagon peptide was included in this group of high-cost biopharmaceuticals in 2008. Although its main application is the treatment of hypoglycaemia in diabetic patients, it can also be used with patients in an alcoholic coma, for those patients with biliary tract pain, and as a bronchodilator. Therefore, in order to reduce biopharmaceutical production costs, the Brazilian government passed laws focusing on the development and increase of a National Pharmaceutical Industrial Centre, including the demand for the national production of glucagon. For that reason and given the importance and high cost of recombinant glucagon, the purpose of this study was to develop methods to improve production, purification and performance of the biological activity of recombinant glucagon. Glucagon was recombined into a plasmid vector containing a Glutathione S-transferase tag, and the peptide was expressed in a heterologous Escherichia coli system. After purification procedures and molecular analyses, the biological activity of this recombinant glucagon was examined using in vivo assays and showed a highly significant (p < 0.00001) and prolonged effect on glucose levels when compared with the standard glucagon. The experimental procedure described here facilitates the high level production of recombinant glucagon with an extended biological activity.
BASE
In: INSEAD Working Paper No. 2015/20/EFE
SSRN
Working paper
In: Tilburg Law Review 20 (2015) 191-212
SSRN
In: CEPS Essay, No. 20/16 December 2015
SSRN
In: Melbourne Institute Working Paper No. 20/15
SSRN
Working paper
In: 20 Review of Constitutional Studies 177, 2015
SSRN